Phenyl bioisosteres in medicinal chemistry: discovery of novel γ-secretase modulators as a potential treatment for Alzheimer's disease.


Journal

RSC medicinal chemistry
ISSN: 2632-8682
Titre abrégé: RSC Med Chem
Pays: England
ID NLM: 101759460

Informations de publication

Date de publication:
26 May 2021
Historique:
received: 11 02 2021
accepted: 23 03 2021
entrez: 14 6 2021
pubmed: 15 6 2021
medline: 15 6 2021
Statut: epublish

Résumé

Phenyl rings are one of the most prevalent structural moieties in active pharmaceutical ingredients, even if they often contribute to poor physico-chemical properties. Herein, we propose the use of a bridged piperidine (BP) moiety as a phenyl bioisostere, which could also be seen as a superior phenyl alternative as it led to strongly improved drug like properties, in terms of solubility and lipophilicity. Additionally, this BP moiety compares favorably to the recently reported saturated phenyl bioisosteres. We applied this concept to our γ-secretase modulator (GSM) project for the potential treatment of Alzheimer's disease delivering clinical candidates.

Identifiants

pubmed: 34124674
doi: 10.1039/d1md00043h
pii: d1md00043h
pmc: PMC8152580
doi:

Types de publication

Journal Article

Langues

eng

Pagination

758-766

Informations de copyright

This journal is © The Royal Society of Chemistry.

Déclaration de conflit d'intérêts

There is no conflict of interest to declare.

Références

ACS Med Chem Lett. 2016 Nov 15;8(1):43-48
pubmed: 28105273
BMC Genomics. 2013 Apr 30;14:290
pubmed: 23627794
Neural Regen Res. 2019 Oct;14(10):1661-1671
pubmed: 31169172
J Med Chem. 2020 Oct 22;63(20):11585-11601
pubmed: 32678591
Chemistry. 2019 Mar 27;25(18):4590-4647
pubmed: 30387906
Drug Discov Today. 2010 Aug;15(15-16):648-55
pubmed: 20570751
RSC Med Chem. 2021 Jan 7;12(4):448-471
pubmed: 33937776
Org Biomol Chem. 2019 Mar 13;17(11):2839-2849
pubmed: 30672560
Science. 1991 Feb 8;251(4994):675-8
pubmed: 1899488
J Med Chem. 2012 Apr 12;55(7):3414-24
pubmed: 22420884
ChemMedChem. 2017 Apr 20;12(8):590-598
pubmed: 28319646
Bioorg Med Chem Lett. 2014 Dec 15;24(24):5731-5737
pubmed: 25453810
J Med Chem. 2017 Apr 13;60(7):2819-2839
pubmed: 28339198
Biochim Biophys Acta. 2013 Dec;1828(12):2898-907
pubmed: 23791707
J Med Chem. 2016 Aug 25;59(16):7389-409
pubmed: 27007185
Angew Chem Int Ed Engl. 2020 Apr 27;59(18):7161-7167
pubmed: 32060990
Angew Chem Int Ed Engl. 2020 Jul 13;59(29):11866-11870
pubmed: 32346946
Chimia (Aarau). 2020 Oct 28;74(10):803-807
pubmed: 33115564
Biochem Biophys Res Commun. 1984 Aug 16;122(3):1131-5
pubmed: 6236805
J Med Chem. 2009 Nov 12;52(21):6752-6
pubmed: 19827778
J Med Chem. 2019 Feb 14;62(3):1078-1095
pubmed: 30137982
ACS Med Chem Lett. 2017 Apr 24;8(5):516-520
pubmed: 28523103
J Org Chem. 2019 Dec 6;84(23):15106-15117
pubmed: 31553875
Org Lett. 2019 Sep 20;21(18):7199-7203
pubmed: 31294572
J Med Chem. 2020 Aug 13;63(15):8534-8553
pubmed: 32706964
Angew Chem Int Ed Engl. 2020 Nov 9;59(46):20515-20521
pubmed: 32662201
Chem Sci. 2018 May 21;9(23):5295-5300
pubmed: 29997886
ACS Med Chem Lett. 2020 Apr 27;11(6):1257-1268
pubmed: 32551009
Trends Pharmacol Sci. 1991 Oct;12(10):383-8
pubmed: 1763432
ACS Med Chem Lett. 2020 Jul 15;11(8):1548-1554
pubmed: 32832022
J Am Chem Soc. 2017 Dec 13;139(49):17791-17794
pubmed: 29131599
ACS Med Chem Lett. 2019 Feb 17;10(3):312-317
pubmed: 30891132
Clin Pharmacol Ther. 2020 Jan;107(1):211-220
pubmed: 31314925
Angew Chem Int Ed Engl. 2016 Mar 7;55(11):3580-5
pubmed: 26846616

Auteurs

H Ratni (H)

pRED, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland hasane.ratni@roche.com (+41) 61 688 2748.

K Baumann (K)

pRED, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland hasane.ratni@roche.com (+41) 61 688 2748.

P Bellotti (P)

pRED, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland hasane.ratni@roche.com (+41) 61 688 2748.

X A Cook (XA)

pRED, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland hasane.ratni@roche.com (+41) 61 688 2748.

L G Green (LG)

pRED, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland hasane.ratni@roche.com (+41) 61 688 2748.

T Luebbers (T)

pRED, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland hasane.ratni@roche.com (+41) 61 688 2748.

M Reutlinger (M)

pRED, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland hasane.ratni@roche.com (+41) 61 688 2748.

A F Stepan (AF)

pRED, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland hasane.ratni@roche.com (+41) 61 688 2748.

W Vifian (W)

pRED, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland hasane.ratni@roche.com (+41) 61 688 2748.

Classifications MeSH